8-KLeadership Changes

AMGEN INC 8-K Report, Executive Changes (Dec 13, 2012)

Filed December 13, 2012For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on December 13, 2012, to report on the Compensation and Management Development Committee's approval of performance unit awards for the 2013-2015 three-year performance period. These awards are tied to the company's Total Shareholder Return (TSR) relative to the S&P 500 Index. The filing outlines the specific performance goals and payout structure, which are designed to incentivize executive performance and align their compensation with shareholder value creation over the specified period.

Key Highlights

  • 1Amgen's Compensation Committee approved performance unit awards for the 2013-2015 performance period.
  • 2Awards are contingent upon Amgen's three-year Total Shareholder Return (TSR) relative to the S&P 500 Index.
  • 3Payouts are structured based on percentile rank of Amgen's TSR against a defined Reference Group within the S&P 500.
  • 4A TSR percentile rank above the 75th percentile can result in a payout of 150%.
  • 5A TSR percentile rank at the 50th percentile (target) will result in a 100% payout.
  • 6Payouts are capped at 400% of the granted performance unit value.
  • 7An amendment to the Performance Program allows for approval of goals and awards prior to the start of the performance period.

Frequently Asked Questions

This 8-K filing announces the approval of performance unit awards for Amgen's executive compensation program for the 2013-2015 performance period. The awards are designed to incentivize management by linking a portion of their compensation to the company's performance as measured by Total Shareholder Return (TSR) relative to the S&P 500.

The number of performance units earned will be determined by Amgen's three-year TSR compared to the TSR of companies within the S&P 500 Index. The payout percentage increases with Amgen's percentile rank against this group, with a target of 100% payout at the 50th percentile and a potential 150% payout above the 75th percentile.

Yes, there are two key limitations. First, if Amgen's TSR is negative, the earned payout percentage cannot exceed 100%. Second, the total value of the earned performance units is capped at 400% of the initial value of the units granted, based on the stock price on the grant date.

The amendment allows the Compensation Committee to approve performance goals and awards for a given performance period before that period begins. Previously, these approvals had to occur within the first 90 days of the period. This change offers more flexibility and allows for earlier alignment between executive incentives and strategic objectives.